By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Free, every week, no sponsor.

Monday, The Root Room. You watch a real health claim try to work on somebody.

Wednesday, Plain Talk. You take that claim apart in plain language, and the receipts sit at the foot of it.

Tuesday and Friday, The Open Site File. What the job actually looks like from inside a clinical trial site. If you have ever thought about moving into clinical research coordinating, start there: roottorx.com/t/open-site-file

Sunday, The Roots, on LinkedIn. A weekly letter for the people who get asked, the ones whose family treats them as the medical desk: linkedin.com/showcase/root-to-rx

Plain Talk is Root to Rx's plain-language teardown: the myth, the evidence, and the one question that beats it.

If you’ve ever had a shot for back pain, somebody made that injection in a room you will never see. This is about what’s supposed to happen in that room, what happened the year nobody checked, and why it’s happening again right now in a different aisle.

In 2012 a pharmacy outside Boston shipped roughly 17,500 vials of a steroid injection, the kind given for back and joint pain, to 75 medical facilities across 23 states. 3 of those batches carried a fungus. 751 people got sick. 64 of them died. Here’s the part that’s hard to sit with: the pharmacy had been finding mold and bacteria in its own clean room all year, and kept shipping anyway.

In a plant that makes injectable medicine, somebody swabs the surfaces every single day and sends them to a lab. If anything grows that should not be there, production stops. Not slows down. Stops. That’s not a courtesy. It’s a set of federal rules, and they cover where the ingredients came from, who handled them, how the room is watched and what gets tested at every stage rather than only at the end. The rules exist because you cannot look at a finished vial and see everything that got into it on the way.  The pharmacy in 2012 had that monitoring system. It found things. It kept going. Its owner was later convicted of racketeering and pleaded guilty to manslaughter.

This isn’t only a 2012 story. There’s a market right now selling injectable compounds online. They’re called peptides, and the vials carry a label that says research use only.

Here’s what that phrase does and does not mean. It’s not a lighter set of rules. There’s no research-use-only category for medicines at all. The phrase comes from laboratory test kits, and it has been borrowed. Nothing requires the seller to make the product under the daily-swab rules. Nothing requires anyone independent to check what’s in the vial before it ships. The sellers say so themselves, on their own labels: not evaluated by the FDA, not for human use.

The pharmacy in 2012 at least had a system watching the room, and ignored what it kept finding. This market has no requirement to look in the first place.

The label lists a molecule. It does not list the room it came out of.

"Same ingredient" tells you almost nothing about safety. The floor it was made on tells you almost everything, and that's exactly the part no label shows you.

64 people died. 751 one got sick. It’s in the public record, the owner went to prison for it, and almost nobody has heard of it.

That’s not because it was hidden. It’s because nobody passed it on.

I’ve spent my career around the industry with GMP certified manufacturing plants like the one in this story. The rules in it are not bureaucracy and they are not there to slow anybody down. They exist because somebody already found out what happens without them, and the finding out cost 64 people their lives. Every one of those rules is somebody's bad day, written down so it does not have to happen to you.

You know someone who has had a shot for back pain. A parent, a coworker, the person who cuts your hair. They have never once thought about the room it was made in, and they have no reason to until somebody tells them.

Be the person who tells them. Send them this one. That is the whole ask.

This is the part of the newsletter where I collect the other side of it: the moments people actually changed their minds about clinical research, and what did it.

Three sentences is all it takes. What you used to believe. What changed it. Where you are now. You do not have to have landed anywhere tidy, and you are allowed to still be suspicious about half of it. That is the honest version and it is the one worth printing.

For this issue, the easiest way in: had you heard of this case before today, and did it change anything?

Reply to this email, or leave a comment on the newsletter. I print one in an issue when somebody sends a good one.

If you did send it on, the referral program counts it. Series 1 cards are the reward.

Every claim above, with how good the evidence behind it is. Tier 3 is an institutional or regulatory record. Tier 4 is an industry or individual report, which means treat it as a lead rather than a finding.

751 infections and 64 deaths, NECC 2012. Tier 3, CDC and FDA.

Barry Cadden, racketeering conviction 2017 and involuntary manslaughter plea 2024. Tier 3, DOJ and Michigan Attorney General. Adjudicated, so safe to name.

What cGMP requires. The regulation text itself, 21 CFR Parts 210 and 211.

The peptide market claim carries no number, deliberately. The widely circulated failure rates, 25 to 43 percent depending on who you read, all come from peptide testing labs reporting on the service they sell, and they measure failure to meet a vendor’s own label claim rather than failure against a pharmaceutical standard. Those are two different things, so I cut the number rather than dress it up. What’s left is structural and you can check it yourself: research-use-only products are not manufactured under cGMP and carry no independent verification requirement, which the sellers state on their own labels.

Two Skeptic’s Toolkit questions this issue turns on.

Q6, am I seeing the full picture or only part of the evidence? Same molecule is only part of it; the floor, the testing and the oversight are the rest. Q10, if I am wrong about this, what would that mean? For anyone assuming an unregulated seller is equivalent to a GMP plant, NECC is what wrong looks like.

Next week the newsletter changes shape for a while. Small Doses is twelve viral hits, one a week, taken apart a small dose at a time so the real thing can't take hold. It starts with peptides: what they actually are, which ones are approved and for whom, and why a clean label tells you nothing about the floor it came off.

1. FDA. Multistate Outbreak of Fungal Meningitis and Other Infections. fda.gov
2. Current Good Manufacturing Practice (CGMP) Regulations, 21 CFR Parts 210-211. FDA.
3. U.S. Department of Justice, Office of Public Affairs. Owner of New England Compounding Center Convicted of Racketeering Leading to Nationwide Fungal Meningitis Outbreak.
4. Michigan Attorney General press release, Barry Cadden manslaughter plea, 2024.
5. Peptide purity/independent verification rate data.

Try it yourself: see if you'd have caught this week's costume on your own.

The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type.

Got Skepticism? runs any claim through the same one-question move Sam just used.

Stay in the Room shows you how to disagree without a fight so that you can talk to people about these difficult topics.

The quiz and both games play in your browser at openlabelmedia.com, and I would love to see your results on social.

For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.

Instagram: instagram.com/roottorx  |  Facebook Lab: facebook.com/groups/theroottorxlab  |  TikTok: tiktok.com/@root.to.rx  |  YouTube: youtube.com/@roottorx  |  Threads: threads.com/@roottorx  |  Subscribe: RootToRx.com

You are receiving this because you subscribed at roottorx.com.

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States